Travere Therapeutics, Inc. (TVTX)

Market Cap	586.89M
Revenue (ttm)	209.65M
Net Income (ttm)	-87.05M
Shares Out	75.15M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,096,350
Open	7.84
Previous Close	7.81
Day's Range	7.82 - 8.77
52-Week Range	5.25 - 23.18
Beta	0.53
Analysts	Buy
Price Target	20.57 (+137.8%)
Earnings Date	Nov 7, 2023

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola a...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Eric M. Dube Ph.D.
• Employees: 462
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX

Financial Performance

In 2022, TVTX's revenue was $212.02 million, a decrease of -6.80% compared to the previous year's $227.49 million. Losses were -$278.48 million, 54.6% more than in 2021.

Analyst Forecast

According to 15 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $20.57, which is an increase of 137.80% from the latest price.

Price Target

$20.57

(137.80% upside)

Analyst Consensus: Buy